Login to Your Account

Partners Bioeq, Formycon go public with Lucentis biosimilar challenge

By Marie Powers
News Editor

Wednesday, October 7, 2015
Under-the-radar biosimilars partners Formycon AG and Bioeq GmbH gained altitude by disclosing that they initiated a pivotal phase III trial of FYB201, a biosimilar of ranibizumab (Lucentis, Genentech Inc.), in patients with neovascular age-related macular degeneration (wet AMD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription